[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$faV_es_bgtZQZKvzn0j7lMbY0dMh3cS9oNx5i2Pydp18":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"Ospedale San Raffaele",[4],46,false,8,5,48202,1,27,[14,17,19,21,24,26,28,30],{"name":15,"count":16},"Respiratory Failure",3,{"name":18,"count":16},"Type 1 Diabetes",{"name":20,"count":16},"Hypertension",{"name":22,"count":23},"Pneumothorax",2,{"name":25,"count":23},"Atelectasis",{"name":27,"count":23},"Bronchospasm",{"name":29,"count":23},"Motor Neuron Disease",{"name":31,"count":23},"Diabetes",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06416761","Genetics in the Progression of Nephropathies","2040-05-19","genetic polymorphisms",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,76,105,131,149,176,204,222,247,274,292,318,348,373,400,418,447,465,483,501,527,550,575,605,629,655,685,703,721],{"intervention":37,"totalTrials":11,"cells":47},{"EARLY_PHASE1":48,"PHASE1":51,"PHASE2":53,"PHASE3":55,"PHASE4":57,"NA":59},{"trials":49,"activeCount":50},[],0,{"trials":52,"activeCount":50},[],{"trials":54,"activeCount":50},[],{"trials":56,"activeCount":50},[],{"trials":58,"activeCount":50},[],{"trials":60,"activeCount":11,"soonestReadout":36},[61],{"nctId":34,"briefTitle":35,"status":62,"phases":63,"primaryCompletion":36,"completion":64,"start":65,"enrollment":66,"conditions":67,"interventions":75},"RECRUITING",[],"2041-05-19","2006-05-19",10000,[68,69,70,71,72,20,73,74],"AKI","CKD","Ckd-Mbd","CKD (Chronic Kidney Disease) Stage 5D","ADPKD","Hematologic Malignancy","Bone Marrow Transplant Complications",[37],{"intervention":77,"totalTrials":11,"cells":78},"Midazolam",{"EARLY_PHASE1":79,"PHASE1":81,"PHASE2":83,"PHASE3":85,"PHASE4":87,"NA":103},{"trials":80,"activeCount":50},[],{"trials":82,"activeCount":50},[],{"trials":84,"activeCount":50},[],{"trials":86,"activeCount":50},[],{"trials":88,"activeCount":50},[89],{"nctId":90,"briefTitle":91,"status":92,"phases":93,"primaryCompletion":94,"completion":94,"start":95,"enrollment":96,"conditions":97,"interventions":102},"NCT01941888","Propofol TCI Administered by Gastroenterologists During Endoscopy: a Randomized Double Blind Controlled Study","COMPLETED",[43],"2013-03","2012-05",140,[98,99,100,101],"Propofol","Target Controlled Infusion","Moderate Sedation","Gastrointestinal Endoscopy",[98,77],{"trials":104,"activeCount":50},[],{"intervention":106,"totalTrials":11,"cells":107},"Remifentanil",{"EARLY_PHASE1":108,"PHASE1":110,"PHASE2":112,"PHASE3":114,"PHASE4":116,"NA":129},{"trials":109,"activeCount":50},[],{"trials":111,"activeCount":50},[],{"trials":113,"activeCount":50},[],{"trials":115,"activeCount":50},[],{"trials":117,"activeCount":50},[118],{"nctId":119,"briefTitle":120,"status":92,"phases":121,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":127},"NCT01229527","Comparison Between Two Different Dosages of Remifentanil During Colonoscopy",[43],"2010-12","2009-04",90,[126],"Colonoscopy",[106,106,128],"Meperidine",{"trials":130,"activeCount":50},[],{"intervention":128,"totalTrials":11,"cells":132},{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":139,"PHASE4":141,"NA":147},{"trials":134,"activeCount":50},[],{"trials":136,"activeCount":50},[],{"trials":138,"activeCount":50},[],{"trials":140,"activeCount":50},[],{"trials":142,"activeCount":50},[143],{"nctId":119,"briefTitle":120,"status":92,"phases":144,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":145,"interventions":146},[43],[126],[106,106,128],{"trials":148,"activeCount":50},[],{"intervention":150,"totalTrials":11,"cells":151},"Autologous Conditioned Serum",{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":158,"PHASE4":172,"NA":174},{"trials":153,"activeCount":50},[],{"trials":155,"activeCount":50},[],{"trials":157,"activeCount":50},[],{"trials":159,"activeCount":50},[160],{"nctId":161,"briefTitle":162,"status":92,"phases":163,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":171},"NCT03850080","Autologous Conditioned Serum: Functional and Clinical Results",[41,42],"2018-09-28","2017-10-06",15,[168,169,170],"Knee Osteoarthritis","Osteoarthritis, Knee","Cartilage Degeneration",[150],{"trials":173,"activeCount":50},[],{"trials":175,"activeCount":50},[],{"intervention":177,"totalTrials":11,"cells":178},"Torasemide",{"EARLY_PHASE1":179,"PHASE1":181,"PHASE2":183,"PHASE3":185,"PHASE4":200,"NA":202},{"trials":180,"activeCount":50},[],{"trials":182,"activeCount":50},[],{"trials":184,"activeCount":50},[],{"trials":186,"activeCount":50},[187],{"nctId":188,"briefTitle":189,"status":92,"phases":190,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":198},"NCT06413082","Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment",[42],"2023-07-07","2023-09-03","2021-02-15",38,[20,196,197],"Genetic Predisposition","Drug Effect",[177,199],"Spironolactone",{"trials":201,"activeCount":50},[],{"trials":203,"activeCount":50},[],{"intervention":199,"totalTrials":11,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":218,"NA":220},{"trials":207,"activeCount":50},[],{"trials":209,"activeCount":50},[],{"trials":211,"activeCount":50},[],{"trials":213,"activeCount":50},[214],{"nctId":188,"briefTitle":189,"status":92,"phases":215,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":216,"interventions":217},[42],[20,196,197],[177,199],{"trials":219,"activeCount":50},[],{"trials":221,"activeCount":50},[],{"intervention":223,"totalTrials":11,"cells":224},"Cannabis Sativa extract Oromucosal spray",{"EARLY_PHASE1":225,"PHASE1":227,"PHASE2":229,"PHASE3":231,"PHASE4":243,"NA":245},{"trials":226,"activeCount":50},[],{"trials":228,"activeCount":50},[],{"trials":230,"activeCount":50},[],{"trials":232,"activeCount":50},[233],{"nctId":234,"briefTitle":235,"status":92,"phases":236,"primaryCompletion":237,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":242},"NCT01776970","Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease",[41,42],"2015-12","2013-01",60,[29,241],"Amyotrophic Lateral Sclerosis (ALS)",[223],{"trials":244,"activeCount":50},[],{"trials":246,"activeCount":50},[],{"intervention":248,"totalTrials":11,"cells":249},"Peri",{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":256,"PHASE4":270,"NA":272},{"trials":251,"activeCount":50},[],{"trials":253,"activeCount":50},[],{"trials":255,"activeCount":50},[],{"trials":257,"activeCount":50},[258],{"nctId":259,"briefTitle":260,"status":261,"phases":262,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":268},"NCT03249285","Pharmacogenomics of Hypertension Personalized Medicine (PGX-HT)","UNKNOWN",[42],"2018-03","2018-11","2016-03",300,[20],[248,269],"HCTZ",{"trials":271,"activeCount":50},[],{"trials":273,"activeCount":50},[],{"intervention":269,"totalTrials":11,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":288,"NA":290},{"trials":277,"activeCount":50},[],{"trials":279,"activeCount":50},[],{"trials":281,"activeCount":50},[],{"trials":283,"activeCount":50},[284],{"nctId":259,"briefTitle":260,"status":261,"phases":285,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":286,"interventions":287},[42],[20],[248,269],{"trials":289,"activeCount":50},[],{"trials":291,"activeCount":50},[],{"intervention":293,"totalTrials":11,"cells":294},"Amiloride",{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":301,"PHASE4":314,"NA":316},{"trials":296,"activeCount":50},[],{"trials":298,"activeCount":50},[],{"trials":300,"activeCount":50},[],{"trials":302,"activeCount":50},[303],{"nctId":304,"briefTitle":305,"status":92,"phases":306,"primaryCompletion":307,"completion":307,"start":164,"enrollment":308,"conditions":309,"interventions":313},"NCT06416735","Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant",[42],"2020-07-20",40,[310,311,312],"Hypertension Essential","Salt Excess","Genetic Hypertension",[293],{"trials":315,"activeCount":50},[],{"trials":317,"activeCount":50},[],{"intervention":319,"totalTrials":11,"cells":320},"Mavrilimumab",{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":342,"PHASE4":344,"NA":346},{"trials":322,"activeCount":50},[],{"trials":324,"activeCount":50},[],{"trials":326,"activeCount":50},[327],{"nctId":328,"briefTitle":329,"status":261,"phases":330,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":341},"NCT04397497","Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)",[41],"2020-09-22","2020-11-22","2020-05-22",50,[336,337,338,339,340],"Covid-19","Acute Respiratory Failure","ARDS, Human","Sars-CoV2","Viral Pneumonia",[319],{"trials":343,"activeCount":50},[],{"trials":345,"activeCount":50},[],{"trials":347,"activeCount":50},[],{"intervention":349,"totalTrials":11,"cells":350},"Human pancreatic islet transplantation",{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":367,"PHASE4":369,"NA":371},{"trials":352,"activeCount":50},[],{"trials":354,"activeCount":50},[],{"trials":356,"activeCount":50},[357],{"nctId":358,"briefTitle":359,"status":92,"phases":360,"primaryCompletion":361,"completion":362,"start":363,"enrollment":364,"conditions":365,"interventions":366},"NCT01722682","Bone Marrow vs Liver as Site for Islet Transplantation",[40,41],"2017-09","2017-12","2012-06",9,[18],[349],{"trials":368,"activeCount":50},[],{"trials":370,"activeCount":50},[],{"trials":372,"activeCount":50},[],{"intervention":374,"totalTrials":11,"cells":375},"rhNGF 180 µg\u002Fml eye drops solution",{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":394,"PHASE4":396,"NA":398},{"trials":377,"activeCount":50},[],{"trials":379,"activeCount":50},[],{"trials":381,"activeCount":50},[382],{"nctId":383,"briefTitle":384,"status":92,"phases":385,"primaryCompletion":386,"completion":386,"start":387,"enrollment":388,"conditions":389,"interventions":392},"NCT02609165","Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema",[41],"2017-02","2015-05",45,[390,391],"Retinitis Pigmentosa","Cystoid Macular Edema",[374,393],"vehicle eye drops",{"trials":395,"activeCount":50},[],{"trials":397,"activeCount":50},[],{"trials":399,"activeCount":50},[],{"intervention":393,"totalTrials":11,"cells":401},{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":412,"PHASE4":414,"NA":416},{"trials":403,"activeCount":50},[],{"trials":405,"activeCount":50},[],{"trials":407,"activeCount":50},[408],{"nctId":383,"briefTitle":384,"status":92,"phases":409,"primaryCompletion":386,"completion":386,"start":387,"enrollment":388,"conditions":410,"interventions":411},[41],[390,391],[374,393],{"trials":413,"activeCount":50},[],{"trials":415,"activeCount":50},[],{"trials":417,"activeCount":50},[],{"intervention":419,"totalTrials":11,"cells":420},"Human pancreatic islet",{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":441,"PHASE4":443,"NA":445},{"trials":422,"activeCount":50},[],{"trials":424,"activeCount":50},[],{"trials":426,"activeCount":50},[427],{"nctId":428,"briefTitle":429,"status":92,"phases":430,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":437},"NCT02505893","Minimal Islet Transplant at Diabetes Onset",[41],"2018-05","2023-12","2015-04",6,[436],"Diabetes Mellitus, Type 1",[419,438,439,440],"ATG","Pegylated G-CSF","Rapamycin",{"trials":442,"activeCount":50},[],{"trials":444,"activeCount":50},[],{"trials":446,"activeCount":50},[],{"intervention":438,"totalTrials":11,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":459,"PHASE4":461,"NA":463},{"trials":450,"activeCount":50},[],{"trials":452,"activeCount":50},[],{"trials":454,"activeCount":50},[455],{"nctId":428,"briefTitle":429,"status":92,"phases":456,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":457,"interventions":458},[41],[436],[419,438,439,440],{"trials":460,"activeCount":50},[],{"trials":462,"activeCount":50},[],{"trials":464,"activeCount":50},[],{"intervention":439,"totalTrials":11,"cells":466},{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":477,"PHASE4":479,"NA":481},{"trials":468,"activeCount":50},[],{"trials":470,"activeCount":50},[],{"trials":472,"activeCount":50},[473],{"nctId":428,"briefTitle":429,"status":92,"phases":474,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":475,"interventions":476},[41],[436],[419,438,439,440],{"trials":478,"activeCount":50},[],{"trials":480,"activeCount":50},[],{"trials":482,"activeCount":50},[],{"intervention":440,"totalTrials":11,"cells":484},{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":495,"PHASE4":497,"NA":499},{"trials":486,"activeCount":50},[],{"trials":488,"activeCount":50},[],{"trials":490,"activeCount":50},[491],{"nctId":428,"briefTitle":429,"status":92,"phases":492,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":493,"interventions":494},[41],[436],[419,438,439,440],{"trials":496,"activeCount":50},[],{"trials":498,"activeCount":50},[],{"trials":500,"activeCount":50},[],{"intervention":502,"totalTrials":11,"cells":503},"Tirzepatide",{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":521,"PHASE4":523,"NA":525},{"trials":505,"activeCount":50},[],{"trials":507,"activeCount":50},[],{"trials":509,"activeCount":50},[510],{"nctId":511,"briefTitle":512,"status":261,"phases":513,"primaryCompletion":514,"completion":515,"start":516,"enrollment":517,"conditions":518,"interventions":520},"NCT05659368","Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1",[41],"2024-10","2024-12","2024-01-01",10,[519],"Wolfram Syndrome",[502],{"trials":522,"activeCount":50},[],{"trials":524,"activeCount":50},[],{"trials":526,"activeCount":50},[],{"intervention":528,"totalTrials":11,"cells":529},"CNI free immunosuppression",{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":544,"PHASE4":546,"NA":548},{"trials":531,"activeCount":50},[],{"trials":533,"activeCount":50},[],{"trials":535,"activeCount":50},[536],{"nctId":537,"briefTitle":538,"status":92,"phases":539,"primaryCompletion":540,"completion":363,"start":541,"enrollment":517,"conditions":542,"interventions":543},"NCT01346085","Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation",[40,41],"2009-06","2006-10",[18],[528],{"trials":545,"activeCount":50},[],{"trials":547,"activeCount":50},[],{"trials":549,"activeCount":50},[],{"intervention":551,"totalTrials":11,"cells":552},"Tocilizumab",{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":569,"PHASE4":571,"NA":573},{"trials":554,"activeCount":50},[],{"trials":556,"activeCount":50},[],{"trials":558,"activeCount":50},[559],{"nctId":560,"briefTitle":561,"status":562,"phases":563,"primaryCompletion":564,"completion":237,"start":565,"enrollment":16,"conditions":566,"interventions":568},"NCT01727206","Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease","TERMINATED",[41],"2015-02","2012-11",[567],"Erdheim-Chester Disease",[551],{"trials":570,"activeCount":50},[],{"trials":572,"activeCount":50},[],{"trials":574,"activeCount":50},[],{"intervention":98,"totalTrials":23,"cells":576},{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":583,"PHASE4":585,"NA":591},{"trials":578,"activeCount":50},[],{"trials":580,"activeCount":50},[],{"trials":582,"activeCount":50},[],{"trials":584,"activeCount":50},[],{"trials":586,"activeCount":50},[587],{"nctId":90,"briefTitle":91,"status":92,"phases":588,"primaryCompletion":94,"completion":94,"start":95,"enrollment":96,"conditions":589,"interventions":590},[43],[98,99,100,101],[98,77],{"trials":592,"activeCount":50},[593],{"nctId":594,"briefTitle":595,"status":562,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":604},"NCT03567928","Laryngeal Mask in Upper Gastrointestinal Procedures",[44],"2019-04-10","2018-09-26",16,[601,602,603],"Anesthesia","Airway Device","C.Surgical Procedure; Gastrointestinal",[98],{"intervention":606,"totalTrials":11,"cells":607},"Phosphodiesterase type 5 Inhibitor",{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":612,"PHASE3":614,"PHASE4":616,"NA":618},{"trials":609,"activeCount":50},[],{"trials":611,"activeCount":50},[],{"trials":613,"activeCount":50},[],{"trials":615,"activeCount":50},[],{"trials":617,"activeCount":50},[],{"trials":619,"activeCount":50},[620],{"nctId":621,"briefTitle":622,"status":261,"phases":623,"primaryCompletion":624,"completion":624,"start":625,"enrollment":239,"conditions":626,"interventions":628},"NCT02845765","Fundus Oculi and Erectile Dysfunction",[],"2020-12","2016-02",[627],"Erectile Dysfunction",[606],{"intervention":630,"totalTrials":11,"cells":631},"Infliximab",{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":638,"PHASE4":640,"NA":642},{"trials":633,"activeCount":50},[],{"trials":635,"activeCount":50},[],{"trials":637,"activeCount":50},[],{"trials":639,"activeCount":50},[],{"trials":641,"activeCount":50},[],{"trials":643,"activeCount":50},[644],{"nctId":645,"briefTitle":646,"status":261,"phases":647,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":652,"interventions":654},"NCT03192878","Infliximab Biosimilar in Takayasu's Arteritis",[],"2019-02","2019-07","2017-03-01",30,[653],"Takayasu Arteritis",[630],{"intervention":656,"totalTrials":11,"cells":657},"Acetaminophen",{"EARLY_PHASE1":658,"PHASE1":660,"PHASE2":662,"PHASE3":664,"PHASE4":666,"NA":668},{"trials":659,"activeCount":50},[],{"trials":661,"activeCount":50},[],{"trials":663,"activeCount":50},[],{"trials":665,"activeCount":50},[],{"trials":667,"activeCount":50},[],{"trials":669,"activeCount":50},[670],{"nctId":671,"briefTitle":672,"status":261,"phases":673,"primaryCompletion":674,"completion":675,"start":676,"enrollment":308,"conditions":677,"interventions":681},"NCT02647047","Spinal Versus Epidural Analgesia in Laparotomic Liver Surgery",[44],"2016-11","2016-12","2016-01",[678,679,680],"Secondary Malignant Neoplasm of Liver","Liver Diseases","Liver Neoplasms",[656,682,683,684,683,683],"Ketorolac","Ropivacaine","Sufentanil",{"intervention":682,"totalTrials":11,"cells":686},{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":695,"NA":697},{"trials":688,"activeCount":50},[],{"trials":690,"activeCount":50},[],{"trials":692,"activeCount":50},[],{"trials":694,"activeCount":50},[],{"trials":696,"activeCount":50},[],{"trials":698,"activeCount":50},[699],{"nctId":671,"briefTitle":672,"status":261,"phases":700,"primaryCompletion":674,"completion":675,"start":676,"enrollment":308,"conditions":701,"interventions":702},[44],[678,679,680],[656,682,683,684,683,683],{"intervention":683,"totalTrials":11,"cells":704},{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":711,"PHASE4":713,"NA":715},{"trials":706,"activeCount":50},[],{"trials":708,"activeCount":50},[],{"trials":710,"activeCount":50},[],{"trials":712,"activeCount":50},[],{"trials":714,"activeCount":50},[],{"trials":716,"activeCount":50},[717],{"nctId":671,"briefTitle":672,"status":261,"phases":718,"primaryCompletion":674,"completion":675,"start":676,"enrollment":308,"conditions":719,"interventions":720},[44],[678,679,680],[656,682,683,684,683,683],{"intervention":684,"totalTrials":11,"cells":722},{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":727,"PHASE3":729,"PHASE4":731,"NA":733},{"trials":724,"activeCount":50},[],{"trials":726,"activeCount":50},[],{"trials":728,"activeCount":50},[],{"trials":730,"activeCount":50},[],{"trials":732,"activeCount":50},[],{"trials":734,"activeCount":50},[735],{"nctId":671,"briefTitle":672,"status":261,"phases":736,"primaryCompletion":674,"completion":675,"start":676,"enrollment":308,"conditions":737,"interventions":738},[44],[678,679,680],[656,682,683,684,683,683]]